London-based Nycomed Amersham, the parent company of Nycomed Amersham Imaging, has reported 2001 first-quarter sales of £375 million (about $540.5 million U.S.). At constant exchange rates, the numbers represent growth of 16% over last year, according to the company.
Nycomed Amersham Imaging posted revenue of £221 million for the quarter ($318.5 million), up 13% from 2000 at constant exchange rates. Sales of its portfolio of medical imaging products targeted at the cardiovascular, neurological, and oncology markets grew at 25%. The company noted that x-ray contrast media products in Europe and the U.S. recorded good growth.
Nycomed has also extended its contract to supply contrast media to group purchasing organization Novation through March 2005.
By AuntMinnie.com staff writersApril 24, 2001
Related Reading
Nycomed, Novation extend contract, April 2, 2001
Nycomed acquires Bruker contrast injector, January 24, 2001
E-Z-EM inks European deal with Nycomed-Amersham, December 18, 2000
Nycomed set to distribute TheraSeed, September 20, 2000
Nycomed's spin signal contrast technology enters clinical trials, August 23, 2000
Copyright © 2001 AuntMinnie.com
